| Literature DB >> 28931515 |
.
Abstract
After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody-drug conjugate can be given as a single agent or in combination with chemotherapy. ©2017 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28931515 DOI： 10.1158/2159-8290.CD-NB2017-132
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397